Treatment for bone diseases

A method for treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength in a mammalian subject, which method comprises:

• (a) administering a batch of at least two doses of anti-sclerostin antibodies to a subject in need of such treatment and monitoring the subject to identify when the subject shows a reduced response to a dose of the anti-sclerostin antibody;
• (b) when such a reduced response is identified, allowing the subject a dosing holiday which is greater in length than the time interval been two successive doses in the batch of (a);
• and
• (c) administering to the subject at least one further dose of anti-sclerostin antibody after the dosing holiday of (b).

A method for treating a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength in a mammalian subject, which method comprises:

• (a) administering to a subject in need of such treatment a batch of at least two doses of anti-sclerostin antibody;
• (b) then allowing the subject a dosing holiday which is greater in length than the interval been two successive doses in the batch of (a), where during that interval the subject is administered a different treatment for the bone disorder;
• and
• (c) after the dosing holiday of (b) administering to the subject at least one further dose of anti-sclerostin antibody.

The method of, where:

• (i) in (a) a batch of doses is administered that comprises from two to twelve doses of anti-sclerostin antibody;
• (ii) the interval between doses in (a) is from about one day to twelve weeks;
• (iii) the dosing holiday of (b) is from about six weeks to 24 weeks in length;
• and/or
• (iv) in (c) the subject is administered a batch of from two to twelve doses of anti-sclerostin antibody.